We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Next Generation Sequencing Reveals Genetic Basis for Congenital Cataracts

By LabMedica International staff writers
Posted on 01 Sep 2014
Applying the latest high-throughput, next-generation DNA sequencing technology has enabled researchers in the United Kingdom to diagnose children with rare diseases that are characterized by the formation of congenital cataracts.

Diagnosing which of the more than 100 diseases that cause between 20,000 and 40,000 cases of congenital cataracts each year is often a lengthy, costly, and inconclusive process based on numerous clinical assessments and a detailed family history. More...


Investigators at the University of Manchester (United Kingdom) decided to modernize this process by adapting the latest high-throughput DNA sequencing technology, which is capable of simultaneously scanning for mutations in all the 115 known congenital cataracts genes.

To verify this approach, the investigators evaluated samples from 36 patients and a known positive control. They were able to determine the precise genetic cause of congenital cataracts in 75% of individuals. Among the patient group, 85% were found to have likely pathogenic mutations, all of which occurred in highly conserved domains known to be vital for normal protein function. In one case, results of DNA sequencing aided in diagnosing a patient with Warburg Micro syndrome, an extremely rare disease that is marked by an abnormally small head and the development of severe epilepsy, among other medical issues.

"There are many diseases that involve congenital cataracts but finding the exact reason was always difficult," said contributing author Dr. Graeme Black, professor of genetics and ophthalmology at the University of Manchester. "Even with a family history, diagnosing these rare diseases was always a bit of a shot in the dark."

The DNA-based test, which was described in the August 19, 2014, online edition of the journal Ophthalmology, was certified for diagnostic use by the United Kingdom's National Health Service in December 2013.

Related Links:

University of Manchester


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Gel Cards
DG Gel Cards
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.